Literature DB >> 35688581

Risk factors for invasive and non-invasive ventilatory support and mortality in hospitalized patients with COVID-19.

N Chebotareva1, S Berns2, T Androsova3, S Moiseev3.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35688581      PMCID: PMC9172211          DOI: 10.1016/j.medine.2021.04.014

Source DB:  PubMed          Journal:  Med Intensiva (Engl Ed)        ISSN: 2173-5727


× No keyword cloud information.
Dear Editor, The mortality rates in patients with COVID-19 pneumonia depend largely on the need to start oxygen supply and the level of respiratory support. In a nationwide study of 1522 consecutive patients with COVID-19 admitted to the Russian intensive care units, the mortality rate was low in patients requiring oxygen supply only (10.1%) and significantly higher in patients who required non-invasive (36.8%) or invasive (76.5%) ventilation. Recently, P. Ramírez et al. published data on ARDS patients admitted to a medical critical care unit (MCCU) and showed the lower mortality (23.5%). The aim of our retrospective study was to investigate the risk factors for NI/I-VS and mortality in 1268 hospitalized patients (638 males and 630 females; median age 63 [52-75] years) with COVID-19 who had completed their hospital stay (death or recovery) from April to June 2020. A diagnosis of COVID-19 was confirmed by polymerase chain reaction on nasopharyngeal swab and/or chest CT (4 or 5 on CO-RADS scale). The extent of lung involvement on CT was classified as none (0%), minimal (1–25%), mild (26–50%), moderate (51–75%), or severe (76–100%) (Table 1 ).
Table 1

Clinical and demographic characteristics of 1268 hospitalised patients with COVID-19.

Baseline characteristicsValue
Median age (IQR), years63 (52–75)
Males, n (%)645 (50.4)



Concomitant diseases, n (%)
 Arterial hypertension742 (58.0)
 Diabetes mellitus264 (20.6)
 Obesity495 (38.7)
 History of stroke79 (6.2)
 Coronary heart disease170 (13.4)
 Heart failure46 (3.6)
 COPD88 (6.9)
 Malignant neoplasms59 (4.6)



Median BMI (IQR), kg/m229.5 (24.8–32.4)



The extent of lung involvement on CT, n (%)
 0%45 (3.5)
 1–25%256 (20)
 26–50%558 (43.5)
 51–75%331 (26.0)
 76–100%90 (7.0)



Respiratory support, n (%)
 None541 (42.2)
 Oxygen by nasal cannula619 (48.4)
 Non-invasive ventilatory support42 (3.3)
 Invasive ventilatory support78 (6.1)

IQR: interquartile range; BMI: body mass index.

Clinical and demographic characteristics of 1268 hospitalised patients with COVID-19. IQR: interquartile range; BMI: body mass index. A total of 731 (57.6%) of 1268 patients required supplemental oxygen. Most of them received oxygen therapy via nasal cannulas, whereas NI/I-VS was started in 119 (9.4%) patients (Table 1). Among patients on NI/I-VS, the mortality rate was significantly higher than among patients who did not require oxygen therapy or were treated with oxygen via nasal cannulas (59.7% and 7.9%, respectively, OR 29.004 [19.71–42.68], p  < 0.001). In univariate logistic model, the following factors were associated with the requirement for NI/I-VS: the maximum CRP and D-dimer levels, prolonged APTT, the extent of bilateral lung involvement, arterial hypertension, coronary heart disease, and diabetes mellitus. Among them, CRP, aPTT, D-dimer, the extent of lung involvement, and arterial hypertension retained statistical significance in multivariate logistic regression model (Table 2 ).
Table 2

Logistic regression model of NI/I-VS risk in COVID-19 patients.

VariatesOR unadjusted95% CI
pOR adjusted95% CI
p
LowerUpperLowerUpper
Age0.9980.9871.0100.7780.9890.9631.0160.406
Male sex0.8810.6051.2840.5100.8000.3371.9010.614
Arterial hypertension3.7382.3016.0710.00013.7711.34210.6000.012
Diabetes mellitus2.1481.4333.2190.00011.1760.4832.8610.721
Obesity0.9630.6821.3580.8291.0830.4482.6220.859
CHD2.2341.1484.3480.0182.1130.5348.3540.286
COPD0.6760.2391.9110.4610.1860.0142.4090.198
Stroke1.1550.6532.0430.6211.7700.6075.1610.295
Heart failure0.9000.3152.5690.8440.6740.0676.7860.738
Malignant neoplasms1.6160.6114.2740.3330.0860.0023.5890.198
Sum of concomitant diseases1.1090.9181.3380.2830.9730.6921.3680.874
CT score4.4993.3885.9730.00016.5193.56211.9300.0001
CRP max1.1091.1071.1110.00011.1081.1041.1130.0001
aPTT max1.0491.0361.0620.00011.0591.0311.0870.0001
D-dimer max1.4261.2531.6220.00011.3101.0261.6710.030

Multivariate model was adjusted for age, sex, maximum aPTT, CRP, ferritin, D-dimer, lactate dehydrogenase levels, CT score, presence and absence of diabetes mellitus and arterial hypertension, obesity, coronary heart disease, stroke, chronic obstructive pulmonary disease, heart failure, malignant neoplasms, sum of underlying diseases in the logistic regression model.

aPTT: activated partial thromboplastin time; CHD: coronary heart disease; CRP: C-reactive protein; CT: computer tomography; COPD: chronic obstructive pulmonary disease.

Logistic regression model of NI/I-VS risk in COVID-19 patients. Multivariate model was adjusted for age, sex, maximum aPTT, CRP, ferritin, D-dimer, lactate dehydrogenase levels, CT score, presence and absence of diabetes mellitus and arterial hypertension, obesity, coronary heart disease, stroke, chronic obstructive pulmonary disease, heart failure, malignant neoplasms, sum of underlying diseases in the logistic regression model. aPTT: activated partial thromboplastin time; CHD: coronary heart disease; CRP: C-reactive protein; CT: computer tomography; COPD: chronic obstructive pulmonary disease. Our findings showed that the need in NI/I-VS was associated with a seven-fold increase in the mortality rates in the large cohort of the consecutive hospitalized patients with COVID-19. The lower mortality in work Ramírez et al. might be explained by therapy with steroids and tocilizumab in almost all patients (95.5%). Lung pathology in COVID-19 shows extensive alveolar and interstitial inflammation and microvascular thrombosis. Infection, coagulation factors and innate immune effector systems (macrophages, neutrophils and the complement system) interact in a process termed immunothrombosis (or thromboinflammation), which is the convergence of thrombosis and inflammation. The role of increased levels of inflammatory markers as well as D-dimer in the development of acute respiratory distress syndrome confirms this concept.4, 5 In conclusion, systemic inflammatory response and coagulation disorders, as well as arterial hypertension were associated with the requirement for NI/I-VS in hospitalized COVID-19 patients.

Ethical approval

The study was approved by the local ethics committee of the Zhadkevich City Clinical Hospital, Moscow (approval certificate no. 07-20).

Funding

None declared.

Conflict of interest

The authors do not have any conflicts of interest to declare.
  4 in total

1.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.

Authors:  Chaomin Wu; Xiaoyan Chen; Yanping Cai; Jia'an Xia; Xing Zhou; Sha Xu; Hanping Huang; Li Zhang; Xia Zhou; Chunling Du; Yuye Zhang; Juan Song; Sijiao Wang; Yencheng Chao; Zeyong Yang; Jie Xu; Xin Zhou; Dechang Chen; Weining Xiong; Lei Xu; Feng Zhou; Jinjun Jiang; Chunxue Bai; Junhua Zheng; Yuanlin Song
Journal:  JAMA Intern Med       Date:  2020-07-01       Impact factor: 21.873

2.  Novel risk scoring system for predicting acute respiratory distress syndrome among hospitalized patients with coronavirus disease 2019 in Wuhan, China.

Authors:  Mengyuan Liang; Miao He; Jian Tang; Xinliang He; Zhijun Liu; Siwei Feng; Ping Chen; Hui Li; Yu'e Xue; Tao Bai; Yanling Ma; Jianchu Zhang
Journal:  BMC Infect Dis       Date:  2020-12-17       Impact factor: 3.090

3.  Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia, Spain.

Authors:  P Ramírez; M Gordón; M Martín-Cerezuela; E Villarreal; E Sancho; M Padrós; J Frasquet; G Leyva; I Molina; M Barrios; S Gimeno; Á Castellanos
Journal:  Med Intensiva (Engl Ed)       Date:  2020-07-11

4.  Outcomes of intensive care unit patients with COVID-19: a nationwide analysis in Russia.

Authors:  S Moiseev; S Avdeev; M Brovko; N Bulanov; E Tao; V Fomin
Journal:  Anaesthesia       Date:  2020-10-05       Impact factor: 12.893

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.